I like this post. We are slowly transitioning to a period where...

I like this post. We are slowly transitioning to a period where PER could potentially become a more interesting prospect to Pharma companies. For exactly the reasons RYNZN points out.

The double blinded placebo controlled trial, and tox study, all supported with targeted Biomarkers are all risk reducing. We just need to replicate the results from the last trial.

The market cap is very low for where PER is in this process. But the market still hates risk. These future announcements will address this.

As Sam says, we wait.